Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management
| Autor: | Paolo Fava, Chiara Astrua, Paola Savoia |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Drug Oncology medicine.medical_specialty Skin Neoplasms media_common.quotation_subject medicine.medical_treatment Immunology Ipilimumab 03 medical and health sciences 0302 clinical medicine Immune system Product Review Internal medicine medicine Humans Immunology and Allergy CTLA-4 Antigen Adverse effect Melanoma media_common Pharmacology Clinical Trials as Topic Chemotherapy business.industry Antibodies Monoclonal Immunotherapy medicine.disease Discontinuation 030104 developmental biology 030220 oncology & carcinogenesis business medicine.drug |
| Zdroj: | Human Vaccines & Immunotherapeutics. 12:1092-1101 |
| ISSN: | 2164-554X 2164-5515 |
| Popis: | In the last years the onset of new therapies changed the management of malignant melanoma. Anti CTLA-4 antibody ipilimumab was the first drug to achieve a significant improvement in survival of advanced stage melanoma. This new therapeutic agent is characterized by a number of side effects that are totally different from those of traditional chemotherapy, mainly caused by the immune system activation. The purpose of this paper is to underline the central role of ipilimumab in the treatment of metastatic melanoma and to characterize related adverse events in terms of incidence, duration and severity of presentation. The early recognition of these side effects is crucial in order to ensure an appropriate management of the toxicities, thus reducing the long term clinical sequelae and the inappropriate treatment discontinuation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|